Atropos Health, a California-based real-world data platform, has completed a strategic financing round with investors including Sumitomo Corporation Venture Group's Presidio Ventures, Samsung Next, Audere Capital, Gaingels, and others.
Atropos Health offers AI-driven innovations, evidence generation, analytics augmentation, and data evaluation to help physicians access real-world evidence for clinical decisions and research.
Their clinical informatics services, called Green Button, provide observational study reports within 48 hours based on user's clinical questions. The company plans to use the funds to expand globally, initially focusing on customers in Brazil and Japan.
Atropos Health aims to address the lack of representation in clinical trials and bridge the evidence gap both in the U.S. and globally. They have previously secured $14 million in a Series A funding round and have been expanding into the life sciences sector through partnerships and advisory boards.
Click here to read the original news story.